About pharming group nv - PHAR
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.
PHAR At a Glance
Pharming Group NV
Darwinweg 24
Leiden, Zuid-Holland 2333 CR
| Phone | 31-71-524-74-00 | Revenue | 245.70M | |
| Industry | Pharmaceuticals: Major | Net Income | -10,564,336.40 | |
| Sector | Health Technology | 2023 Sales Growth | 19.424% | |
| Fiscal Year-end | 12 / 2024 | Employees | N/A | |
| View SEC Filings |
PHAR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.057 |
| Price to Book Ratio | 3.506 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -64.212 |
| Enterprise Value to Sales | 2.886 |
| Total Debt to Enterprise Value | 0.242 |
PHAR Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 5.765 |
| Total Asset Turnover | 0.544 |
PHAR Liquidity
| Current Ratio | 4.057 |
| Quick Ratio | 3.329 |
| Cash Ratio | 2.737 |
PHAR Profitability
| Gross Margin | 85.235 |
| Operating Margin | -8.983 |
| Pretax Margin | -4.779 |
| Net Margin | -4.30 |
| Return on Assets | -2.34 |
| Return on Equity | -4.99 |
| Return on Total Capital | -2.707 |
| Return on Invested Capital | -2.813 |
PHAR Capital Structure
| Total Debt to Total Equity | 78.409 |
| Total Debt to Total Capital | 43.949 |
| Total Debt to Total Assets | 36.425 |
| Long-Term Debt to Equity | 75.923 |
| Long-Term Debt to Total Capital | 42.555 |